Latest News and Press Releases

Washington, DC, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) celebrates the recognition of our Chief Medical Officer, Matthew Greenhawt, MD, MBA, MSc, as the...

Excellergy Debuts with $70 Million Series A Financing to Advance First-in-Class Portfolio of Trifunctional Effector Cell Response Inhibitors (ECRIs)

Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The "Allergy Shots Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user,...

Dublin, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The "Nasal Allergy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application,...

Dublin, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The "Allergy Treatment Global Market Report by Type, Treatment, Dosage Form, Distribution Channel, Countries and Company Analysis, 2025-2033" report has...

Dublin, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The "Systemic Mastocytosis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added...

Washington, DC, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) issued the following statement on news that the California Assembly and Senate passed SB 68 –...

In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo Data from these trials will support...

ZURICH, Aug. 15, 2025 (GLOBE NEWSWIRE) -- EAACI has launched its Antibiotic Allergy Awareness Campaign during its 2025 Congress in Glasgow. The initiative begins a global effort to address...

ALK (ALKB:DC / OMX: ALK B) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of the company’s tree pollen tablet ITULAZAX® for the treatment in...